Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies

Sara Capolla,1 Chiara Garrovo,2 Sonia Zorzet,1 Andrea Lorenzon,3 Enrico Rampazzo,4 Ruben Spretz,5 Gabriele Pozzato,6 Luis Núñez,7 Claudio Tripodo,8 Paolo Macor,1,9 Stefania Biffi2 1Department of Life Sciences, University of Trieste, 2Institute for Maternal and Child Health &am...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Capolla S, Garrovo C, Zorzet S, Lorenzon A, Rampazzo E, Spretz R, Pozzato G, Núñez L, Tripodo C, Macor P, Biffi S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/044e56ff57d04839b07ff29732cd2f5a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:044e56ff57d04839b07ff29732cd2f5a
record_format	dspace
spelling	oai:doaj.org-article:044e56ff57d04839b07ff29732cd2f5a2021-12-02T02:32:46ZTargeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies1178-2013https://doaj.org/article/044e56ff57d04839b07ff29732cd2f5a2015-06-01T00:00:00Zhttp://www.dovepress.com/targeted-tumor-imaging-of-anti-cd20-polymeric-nanoparticles-developed--peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Sara Capolla,1 Chiara Garrovo,2 Sonia Zorzet,1 Andrea Lorenzon,3 Enrico Rampazzo,4 Ruben Spretz,5 Gabriele Pozzato,6 Luis Núñez,7 Claudio Tripodo,8 Paolo Macor,1,9 Stefania Biffi2 1Department of Life Sciences, University of Trieste, 2Institute for Maternal and Child Health – IRCCS “Burlo Garofolo”, Trieste, 3Animal Care Unit, Cluster in Biomedicine (CBM scrl), Trieste, Italy; 4Department of Chemistry “G. Ciamician”, University of Bologna, Bologna, Italy; 5LNK Chemsolutions LLC, Lincoln, NE, USA; 6Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy; 7Bio-Target, Inc., University of Chicago, Chicago, IL, USA; 8Department of Human Pathology, University of Palermo, Palermo, Italy; 9Callerio Foundation Onlus, Institutes of Biological Researches, Trieste, Italy Abstract: The expectations of nanoparticle (NP)-based targeted drug delivery systems in cancer, when compared with convectional therapeutic methods, are greater efficacy and reduced drug side effects due to specific cellular-level interactions. However, there are conflicting literature reports on enhanced tumor accumulation of targeted NPs, which is essential for translating their applications as improved drug-delivery systems and contrast agents in cancer imaging. In this study, we characterized biodegradable NPs conjugated with an anti-CD20 antibody for in vivo imaging and drug delivery onto tumor cells. NPs’ binding specificity mediated by anti-CD20 antibody was evaluated on MEC1 cells and chronic lymphocytic leukemia patients’ cells. The whole-body distribution of untargeted NPs and anti-CD20 NPs were compared by time-domain optical imaging in a localized human/mouse model of B-cell malignancy. These studies provided evidence that NPs’ functionalization by an anti-CD20 antibody improves tumor pharmacokinetic profiles in vivo after systemic administration and increases in vivo imaging of tumor mass compared to non-targeted NPs. Together, drug delivery and imaging probe represents a promising theranostics tool for targeting B-cell malignancies. Keywords: active targeting, optical imaging, tumor accumulationCapolla SGarrovo CZorzet SLorenzon ARampazzo ESpretz RPozzato GNúñez LTripodo CMacor PBiffi SDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2015, Iss default, Pp 4099-4109 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Capolla S Garrovo C Zorzet S Lorenzon A Rampazzo E Spretz R Pozzato G Núñez L Tripodo C Macor P Biffi S Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies
description	Sara Capolla,1 Chiara Garrovo,2 Sonia Zorzet,1 Andrea Lorenzon,3 Enrico Rampazzo,4 Ruben Spretz,5 Gabriele Pozzato,6 Luis Núñez,7 Claudio Tripodo,8 Paolo Macor,1,9 Stefania Biffi2 1Department of Life Sciences, University of Trieste, 2Institute for Maternal and Child Health – IRCCS “Burlo Garofolo”, Trieste, 3Animal Care Unit, Cluster in Biomedicine (CBM scrl), Trieste, Italy; 4Department of Chemistry “G. Ciamician”, University of Bologna, Bologna, Italy; 5LNK Chemsolutions LLC, Lincoln, NE, USA; 6Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy; 7Bio-Target, Inc., University of Chicago, Chicago, IL, USA; 8Department of Human Pathology, University of Palermo, Palermo, Italy; 9Callerio Foundation Onlus, Institutes of Biological Researches, Trieste, Italy Abstract: The expectations of nanoparticle (NP)-based targeted drug delivery systems in cancer, when compared with convectional therapeutic methods, are greater efficacy and reduced drug side effects due to specific cellular-level interactions. However, there are conflicting literature reports on enhanced tumor accumulation of targeted NPs, which is essential for translating their applications as improved drug-delivery systems and contrast agents in cancer imaging. In this study, we characterized biodegradable NPs conjugated with an anti-CD20 antibody for in vivo imaging and drug delivery onto tumor cells. NPs’ binding specificity mediated by anti-CD20 antibody was evaluated on MEC1 cells and chronic lymphocytic leukemia patients’ cells. The whole-body distribution of untargeted NPs and anti-CD20 NPs were compared by time-domain optical imaging in a localized human/mouse model of B-cell malignancy. These studies provided evidence that NPs’ functionalization by an anti-CD20 antibody improves tumor pharmacokinetic profiles in vivo after systemic administration and increases in vivo imaging of tumor mass compared to non-targeted NPs. Together, drug delivery and imaging probe represents a promising theranostics tool for targeting B-cell malignancies. Keywords: active targeting, optical imaging, tumor accumulation
format	article
author	Capolla S Garrovo C Zorzet S Lorenzon A Rampazzo E Spretz R Pozzato G Núñez L Tripodo C Macor P Biffi S
author_facet	Capolla S Garrovo C Zorzet S Lorenzon A Rampazzo E Spretz R Pozzato G Núñez L Tripodo C Macor P Biffi S
author_sort	Capolla S
title	Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies
title_short	Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies
title_full	Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies
title_fullStr	Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies
title_full_unstemmed	Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies
title_sort	targeted tumor imaging of anti-cd20-polymeric nanoparticles developed for the diagnosis of b-cell malignancies
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/044e56ff57d04839b07ff29732cd2f5a
work_keys_str_mv	AT capollas targetedtumorimagingofanticd20polymericnanoparticlesdevelopedforthediagnosisofbcellmalignancies AT garrovoc targetedtumorimagingofanticd20polymericnanoparticlesdevelopedforthediagnosisofbcellmalignancies AT zorzets targetedtumorimagingofanticd20polymericnanoparticlesdevelopedforthediagnosisofbcellmalignancies AT lorenzona targetedtumorimagingofanticd20polymericnanoparticlesdevelopedforthediagnosisofbcellmalignancies AT rampazzoe targetedtumorimagingofanticd20polymericnanoparticlesdevelopedforthediagnosisofbcellmalignancies AT spretzr targetedtumorimagingofanticd20polymericnanoparticlesdevelopedforthediagnosisofbcellmalignancies AT pozzatog targetedtumorimagingofanticd20polymericnanoparticlesdevelopedforthediagnosisofbcellmalignancies AT nunezl targetedtumorimagingofanticd20polymericnanoparticlesdevelopedforthediagnosisofbcellmalignancies AT tripodoc targetedtumorimagingofanticd20polymericnanoparticlesdevelopedforthediagnosisofbcellmalignancies AT macorp targetedtumorimagingofanticd20polymericnanoparticlesdevelopedforthediagnosisofbcellmalignancies AT biffis targetedtumorimagingofanticd20polymericnanoparticlesdevelopedforthediagnosisofbcellmalignancies
_version_	1718402386887704576

Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies

Ejemplares similares